Repros Therapeutics, Inc.

The European Medicines Agency’s key scientific committee, the CHMP, this week recommended approval of seven products, the same number as in December 2017. They include Roche ’s Hemlibra (emic

EU regulators will decide this week decide whether several new treatments – including Roche’s hemophilia drug, Hemlibra (emicizumab), which is being fast-tracked through the system – should be recom

The US FDA's draft guidance on drug development in male hypogonadotropic hypogonadism does not apply to testosterone products such as Clarus Therapeutics Inc. ' Jatenzo that are being developed a

IN VITRO DIAGNOSTICS Alliances Oxford Immunotec Global PLC Qiagen NV Oxford Immunotec Global PLC and Qiagen NV have settled patent infringement litigation surrounding Qiagen's QuantiFERON-TB